Generic Central Nervous System Drugs Global Market Report 2024 - Growth, Trends, Analysis, Forecast 2033

"The new report published by The Business Research Company, titled Generic Central Nervous System Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the generic central nervous system drugs market size has grown strongly in recent years. It will grow from $83.71 billion in 2023 to $89.47 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $117.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp

Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market
The increasing incidence of mental health disorders is expected to propel the growth of the generic central nervous system (CNS) drug market going forward. A mental health disorder is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. It is usually linked to distress or functional impairment in key areas. Generic central nervous system (CNS) drugs play a crucial role in the management of mental health disorders by providing affordable and accessible treatment options. For instance, in November 2022, according to the Health and Social Care Information Centre, a UK-based federal body that offers content, data, and computer systems for experts, physicians, and controllers in the social and healthcare sectors, the proportion of 17- to 19-year-olds with a suspected mental disorder grew from 17.4% in 2021 to 25.7% in 2022. Therefore, the increasing incidence of mental health disorders is driving the generic central nervous system (CNS) drug market.

Innovative Solutions Drive Growth In Generic Central Nervous System Drugs Market
Product innovations have emerged as a key trend gaining popularity in the generic central nervous system drugs market. Major companies operating in the generic central nervous system drugs market are focused on developing innovative products and solutions to strengthen their position in the market. For instance, in December 2021, Intra-Cellular Therapies, Inc. a US-based biopharmaceutical company launched CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. As a monotherapy or adjunctive therapy with lithium or valproate, CAPLYTA is the only medication approved by the FDA to treat depressive disorders associated with bipolar I or bipolar II. When it comes to weight, cardiometabolic parameters, and extrapyramidal symptoms (disturbances in movement), CAPLYTA has consistently demonstrated a positive profile. Approximately 11 million adults in the United States suffer from bipolar I and bipolar II disorder, serious, highly prevalent mental health conditions marked by recurrent episodes of mania or hypomania interspersed with periods of major depression (bipolar depression). About half of all bipolar disorder patients have either bipolar I disorder or bipolar II disorder.

The generic central nervous system drugs market covered in this report is segmented -

1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-the-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9315&type=discount

Major companies operating in the generic central nervous system drugs market report are Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

Contents of the report:
1. Executive Summary
2. Generic Central Nervous System Drugs Market Report Structure
3. Generic Central Nervous System Drugs Market Trends And Strategies
4. Generic Central Nervous System Drugs Market - Macro Economic Scenario
5. Generic Central Nervous System Drugs Market Size And Growth
…..
27. Generic Central Nervous System Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.